Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
PLoS One. 2014 Feb 21;9(2):e88894. doi: 10.1371/journal.pone.0088894. eCollection 2014.
Tissue kallikrein (KLK1) expression is up-regulated in human diabetic kidney tissue and induced by high glucose (HG) in human proximal tubular epithelial cells (PTEC). Since the kallikrein-kinin system (KKS) has been linked to cellular inflammatory process in many diseases, it is likely that KLK1 expression may mediate the inflammatory process during the development of diabetic nephropathy. In this study, we explored the role of KLK1 in tubular pro-inflammatory responses under the diabetic milieu. Recombinant KLK1 stimulated the production of inflammatory cytokines in PTEC via the activation of p42/44 and p38 MAPK signaling pathways. Molecular knockdown of endogenous KLK1 expression by siRNA transfection in PTEC attenuated advanced glycation end-products (AGE)-induced IL-8 and ICAM-1 productions in vitro. Interestingly, exposure of PTEC to KLK1 induced the expression of protease-activated receptors (PARs). There was a 2.9-fold increase in PAR-4, 1.4-fold increase in PAR-1 and 1.2-fold increase in PAR-2 mRNA levels. Activation of PAR-4 by a selective agonist was found to elicit the pro-inflammatory and pro-fibrotic phenotypes in PTEC while blockade of the receptor by specific antagonist attenuated high glucose-induced IL-6, CCL-2, CTGF and collagen IV expression. Calcium mobilization by the PAR-4 agonist in PTEC was desensitized by pretreatment with KLK1. Consistent with these in vitro findings, there was a markedly up-regulation of tubular PAR-4 expression in human diabetic renal cortical tissues. Together, these results suggest that up-regulation of KLK1 in tubular epithelial cells may mediate pro-inflammatory pathway and PAR activation during diabetic nephropathy and provide a new therapeutic target for further investigation.
组织激肽释放酶(KLK1)在人糖尿病肾病组织中表达上调,并在人近端肾小管上皮细胞(PTEC)中被高葡萄糖(HG)诱导。由于激肽释放酶-激肽系统(KKS)与许多疾病中的细胞炎症过程有关,因此 KLK1 的表达可能介导糖尿病肾病发展过程中的炎症过程。在这项研究中,我们探讨了 KLK1 在糖尿病环境下肾小管前炎症反应中的作用。重组 KLK1 通过激活 p42/44 和 p38 MAPK 信号通路刺激 PTEC 中炎症细胞因子的产生。用 siRNA 转染在 PTEC 中对内源性 KLK1 表达进行分子敲低,可减弱体外晚期糖基化终产物(AGE)诱导的 IL-8 和 ICAM-1 的产生。有趣的是,PTEC 暴露于 KLK1 诱导蛋白酶激活受体(PARs)的表达。PAR-4 的 mRNA 水平增加了 2.9 倍,PAR-1 增加了 1.4 倍,PAR-2 增加了 1.2 倍。发现选择性激动剂激活 PAR-4 可在 PTEC 中引发前炎症和促纤维化表型,而用特异性拮抗剂阻断受体可减弱高葡萄糖诱导的 IL-6、CCL-2、CTGF 和胶原 IV 的表达。用 KLK1 预处理可使 PAR-4 激动剂引起的 PTEC 钙动员脱敏。与这些体外发现一致,在人糖尿病肾皮质组织中观察到肾小管 PAR-4 表达明显上调。综上所述,KLK1 在肾小管上皮细胞中的上调可能在糖尿病肾病中介导前炎症途径和 PAR 激活,并为进一步研究提供了一个新的治疗靶点。